A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
Authors:
Open Access
- 29 December 2009
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 10 (3) , 191-199
Abstract
The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation. Past pharmacogenetic research has not explained this variation. Patients with prostate cancer enrolled in a randomized phase II trial using docetaxel and thalidomide versus docetaxel alone were genotyped using the Affymetrix DMET 1.0 platform, which tests for 1256 genetic variations in 170 drug disposition genes. Genetic polymorphisms were analyzed for associations with clinical response and toxicity. In all, 10 single-nucleotide polymorphisms (SNPs) in three genes were potentially associated with response to therapy: peroxisome proliferator-activated receptor-δ (PPAR-δ), sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) and carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3). In addition, 11 SNPs in eight genes were associated with toxicities to treatment: spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), CHST3, cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), ATPase, Cu++ transporting, alpha polypeptide (ATP7A), cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and solute carrier family 10 (sodium/bile acid cotransporter family), member 2 (SLC10A2). Genotyping results between drug metabolizing enzymes and transporters (DMET) and direct sequencing showed >96% of concordance. These findings highlight the role that non-CYP450 metabolizing enzymes and transporters may have in the pharmacology of docetaxel and thalidomide.Keywords
This publication has 57 references indexed in Scilit:
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with DocetaxelClinical Cancer Research, 2008
- Association Study of Wnt Signaling Pathway Genes in Bipolar DisorderArchives of General Psychiatry, 2008
- Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patientsGenes, Chromosomes and Cancer, 2008
- Association of a CYP17 Polymorphism with Overall Survival in Caucasian Patients with Androgen-Independent Prostate CancerUrology, 2007
- Transcriptional network governing the angiogenic switch in human pancreatic cancerProceedings of the National Academy of Sciences, 2007
- Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsAnti-Cancer Drugs, 2007
- Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of DocetaxelClinical Cancer Research, 2006
- Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugsCritical Reviews in Oncology/Hematology, 2005
- Enzymatic Properties, Tissue-Specific Expression, and Lysosomal Location of Two Highly Homologous Rat SULT1C2 SulfotransferasesBiochemical and Biophysical Research Communications, 2000
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999